Nurix Therapeutics, Inc.

NasdaqGM:NRIX Stock Report

Market Cap: US$714.7m

Nurix Therapeutics Future Growth

Future criteria checks 2/6

Nurix Therapeutics's earnings are forecast to decline at 4.2% per annum while its annual revenue is expected to grow at 30% per year. EPS is expected to grow by 1.8% per annum. Return on equity is forecast to be -202.4% in 3 years.

Key information

-4.2%

Earnings growth rate

1.8%

EPS growth rate

Biotechs earnings growth20.6%
Revenue growth rate30.0%
Future return on equity-202.4%
Analyst coverage

Good

Last updated25 Mar 2024

Recent future growth updates

Recent updates

Improved Revenues Required Before Nurix Therapeutics, Inc. (NASDAQ:NRIX) Shares Find Their Feet

Feb 20
Improved Revenues Required Before Nurix Therapeutics, Inc. (NASDAQ:NRIX) Shares Find Their Feet

Nurix Therapeutics: Recovering Thanks To ASH, But I Think It's Priced Just Right For Now

Jan 16

Here's Why We're Watching Nurix Therapeutics' (NASDAQ:NRIX) Cash Burn Situation

Dec 29
Here's Why We're Watching Nurix Therapeutics' (NASDAQ:NRIX) Cash Burn Situation

Nurix Therapeutics, Inc.'s (NASDAQ:NRIX) 29% Dip In Price Shows Sentiment Is Matching Revenues

Oct 14
Nurix Therapeutics, Inc.'s (NASDAQ:NRIX) 29% Dip In Price Shows Sentiment Is Matching Revenues

Broker Revenue Forecasts For Nurix Therapeutics, Inc. (NASDAQ:NRIX) Are Surging Higher

Oct 13
Broker Revenue Forecasts For Nurix Therapeutics, Inc. (NASDAQ:NRIX) Are Surging Higher

Here's Why We're Watching Nurix Therapeutics' (NASDAQ:NRIX) Cash Burn Situation

Sep 30
Here's Why We're Watching Nurix Therapeutics' (NASDAQ:NRIX) Cash Burn Situation

Party Time: Brokers Just Made Major Increases To Their Nurix Therapeutics, Inc. (NASDAQ:NRIX) Earnings Forecasts

Apr 18
Party Time: Brokers Just Made Major Increases To Their Nurix Therapeutics, Inc. (NASDAQ:NRIX) Earnings Forecasts

We Think Nurix Therapeutics (NASDAQ:NRIX) Needs To Drive Business Growth Carefully

Apr 15
We Think Nurix Therapeutics (NASDAQ:NRIX) Needs To Drive Business Growth Carefully

We're Keeping An Eye On Nurix Therapeutics' (NASDAQ:NRIX) Cash Burn Rate

Nov 28
We're Keeping An Eye On Nurix Therapeutics' (NASDAQ:NRIX) Cash Burn Rate

Nurix Therapeutics GAAP EPS of -$0.90 beats by $0.07, revenue of $10.79M misses by $1.29M

Oct 06

Nurix Therapeutics GAAP EPS of -$1.01 misses by $0.02, revenue of $11.43M beats by $0.93M

Jul 07

FDA approves expansion of Nurix Therapeutics' phase 1 trial of NX-1607 into the U.S.

Jun 30

We Think Nurix Therapeutics (NASDAQ:NRIX) Needs To Drive Business Growth Carefully

Jun 21
We Think Nurix Therapeutics (NASDAQ:NRIX) Needs To Drive Business Growth Carefully

We Think Nurix Therapeutics (NASDAQ:NRIX) Can Afford To Drive Business Growth

Mar 07
We Think Nurix Therapeutics (NASDAQ:NRIX) Can Afford To Drive Business Growth

Nurix: Advancing Targeted Protein Modulation Therapies

Nov 21

Companies Like Nurix Therapeutics (NASDAQ:NRIX) Can Afford To Invest In Growth

Nov 21
Companies Like Nurix Therapeutics (NASDAQ:NRIX) Can Afford To Invest In Growth

We're Not Worried About Nurix Therapeutics' (NASDAQ:NRIX) Cash Burn

Jul 24
We're Not Worried About Nurix Therapeutics' (NASDAQ:NRIX) Cash Burn

Nurix Therapeutics appoints new operations chief

Jun 21

Nurix Therapeutics adds Clay Siegall to its board of directors

Jun 01

Here's Why We're Not At All Concerned With Nurix Therapeutics' (NASDAQ:NRIX) Cash Burn Situation

Apr 15
Here's Why We're Not At All Concerned With Nurix Therapeutics' (NASDAQ:NRIX) Cash Burn Situation

Industry Analysts Just Upgraded Their Nurix Therapeutics, Inc. (NASDAQ:NRIX) Revenue Forecasts By 10%

Feb 21
Industry Analysts Just Upgraded Their Nurix Therapeutics, Inc. (NASDAQ:NRIX) Revenue Forecasts By 10%

Nurix Therapeutics, Inc. (NASDAQ:NRIX) Analysts Are Pretty Bullish On The Stock After Recent Results

Feb 18
Nurix Therapeutics, Inc. (NASDAQ:NRIX) Analysts Are Pretty Bullish On The Stock After Recent Results

Rainbows and Unicorns: Nurix Therapeutics, Inc. (NASDAQ:NRIX) Analysts Just Became A Lot More Optimistic

Jan 31
Rainbows and Unicorns: Nurix Therapeutics, Inc. (NASDAQ:NRIX) Analysts Just Became A Lot More Optimistic

Earnings and Revenue Growth Forecasts

NasdaqGM:NRIX - Analysts future estimates and past financials data (USD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
11/30/202689-247-259-2017
11/30/202573-216-245-1669
11/30/202471-178-175-11810
11/30/202377-144-90-81N/A
8/31/202369-149-154-146N/A
5/31/202361-157-161-151N/A
2/28/202342-179-177-166N/A
11/30/202239-180-172-160N/A
8/31/202239-171-163-153N/A
5/31/202239-154-145-136N/A
2/28/202234-135-143-135N/A
11/30/202130-117-90-84N/A
8/31/202129-99-80-74N/A
5/31/202123-89-56-50N/A
2/28/202120-63-38-33N/A
11/30/202018-43-50N/A
8/31/202013-3738N/A
5/31/202019-214750N/A
2/29/202025-244951N/A
11/30/201931-22-11N/A
11/30/201837-9-33-32N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: NRIX is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: NRIX is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: NRIX is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: NRIX's revenue (30% per year) is forecast to grow faster than the US market (8.2% per year).

High Growth Revenue: NRIX's revenue (30% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: NRIX is forecast to be unprofitable in 3 years.


Discover growth companies

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.